ArticleOncology letters2026
Primary bone marrow diffuse large B-cell lymphoma with secondary myelofibrosis: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary bone marrow (BM) diffuse large B-cell lymphoma (PBM-DLBCL) is an extremely rare and highly aggressive subtype of extranodal lymphoma. Its non-specific clinical manifestation, often presenting with pancytopenia, poses significant diagnostic challenges, frequently leading to misdiagnosis as other hematological disorders. In April 2023, a 70-year-old man was hospitalized in the Department of Hematology of The First Affiliated Hospital of Jishou University (Jishou, China). The patient presented to the hospital with fever, malaise and severe pancytopenia. An initial BM biopsy indicated a T-cell lymphoproliferative disorder accompanied by myelofibrosis (MF), for which empirical immunosuppressive therapy was administered without clinical benefit. A total of 10 months later, a repeat BM biopsy demonstrated a distinct population of CD20
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.